73 completed, 5 active not recruiting, 3 recruiting, 3 terminated. 89 Phase 1, 17 Phase 2.
Follow Solutions: new trials by email Literature Review of Solutions trials Research Report on Solutions
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| KF2025#1 Trial: Ketamine, Cannabidiol and Cobicistat Interaction Study Ketamine 10 mg/ml oral solution, UK special, Cobisistat Tybost 150 mg, Cannabidiol Epidyolex 100 mg/ml - Drug Drug Interaction | Phase 1 | Not yet recruiting | Helsinki University Central Hospital | 12 | 2026-03-04 | 2026-03-10 |
| Role of Alpha-to-beta Cell Communication to Adapt Insulin Secretion to Insulin Resistance. Exendin-9 is a 30 amino acid peptide that is an established competitive antagonist of the GLP-1 receptor. Subjects will receive exendin-9 by intravenous infusion at a rate of 600 pmol/kg/min, Dexamethasone, Dextrose 20% solution - Diabetes (DM) | Phase 1 | Recruiting | David D'Alessio, M.D. | 30 | 2025-12-30 | 2026-10-01 |
| A Study on the Treatment of Androgenetic Alopecia in Young Men With Umbilical Cord Mesenchymal Stem Cell Exosomes Human umbilical cord mesenchymal stem cell exosomes, Minoxidil 5% Topical Solution - Androgenic Alopecia | Phase 1 / Phase 2 | Recruiting | Shenzhen People's Hospital | 59 | 2025-09-20 | 2025-12-02 |
| Clinical Study of the Safety and Pharmacokinetics of the Drug Fluorothiazinone, a Concentrate for Solution Preparation for Infusion. ¼ of the full (target) dose (solution, 5 ml), ½ of the full (target) dose (solution, 10 ml), full dose (solution, 20 ml) - Safety and Pharmacokinetics | Phase 1 | Not yet recruiting | Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation | 70 | 2025-09-01 | 2025-09-22 |
| Study on Sapropterin Dihydrochloride Oral Suspension in Healthy Subjects Under Fed Conditions RLF-OD032 100 mg/mL oral suspension, Kuvan 100 MG Powder for Oral Solution - Bioequivalence | Phase 1 | Completed | APR Applied Pharma Research s.a. | 42 | 2025-08-20 | 2026-04-28 |
| A Study of TAK-881 With and Without Ramp-Up Dosing in Healthy Adults TAK-881, SC Investigational Needle Sets - Healthy Volunteers | Phase 1 | Completed | Takeda | 64 | 2025-04-22 | 2026-08-17 |
| Intravenous Immunoglobulin (IVIG) and Blood-Brain Barrier Disruption in Amyotrophic Lateral Sclerosis (ALS) Next Generation Dome Helmet Focused Ultrasound, Intravenous immunoglobulin (IVIG), 10% solution for infusion, Definity® Vial for (Perflutren Lipid Microsphere) Injectable Suspension - Amyotrophic Lateral Sclerosis, ALS | Phase 1 | Active not recruiting | Sunnybrook Health Sciences Centre | 6 | 2025-04-15 | 2026-07-14 |
| A Study of TAK-881 and HyQvia in Healthy Adults TAK-881, HyQvia, SC Investigational Needle Sets - Healthy Volunteers | Phase 1 | Completed | Takeda | 30 | 2025-03-24 | 2026-06-11 |
| Sphenopalatine Ganglion Block and Cold Induced Headaches Lidocaine Topical 4% Topical Solution, Bitrex, normal saline - Cold Induced Headache, Brain Freeze | Phase 1 | Active not recruiting | Wright State University | 30 | 2025-01-01 | 2025-01-31 |
| Different Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic Melanoma pembrolizumab (KEYTRUDA®), BI-1607, Ipilimumab (YervoyTM, 50 mg/10 mL solution) - Melanoma Metastatic, Melanoma of Skin | Phase 1 / Phase 2 | Active not recruiting | BioInvent International AB | 35 | 2024-12-11 | 2026-10-02 |
| A Bioequivalence Study of Two Different Dosage Form of Genakumab Genakumab Injection (T, Solution for injection), Genakumab for Injection (R, Powder for solution for injection) - Gouty Arthritis (GA) | Phase 1 | Completed | Changchun GeneScience Pharmaceutical Co., Ltd. | 178 | 2024-06-24 | 2025-02-11 |
| Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With Advanced Solid Tumors Who Failed Standard Treatments (KEYNOTE F19) XNW5004, KEYTRUDA® (pembrolizumab) 25 mg/mL Solution for Injection - Carcinoma, Squamous Cell Carcinoma of Head and Neck | Phase 1 / Phase 2 | Terminated | Evopoint Biosciences Inc. | 12 | 2023-09-20 | 2026-07-23 |
| A Clinical Trial to Assess Safety and Pharmacokinetics of Fosnetupitant 235 mg and Metabolites in Healthy Volunteers Fosnetupitant 235 mg solution, Akynzeo solution - Healthy Volunteers | Phase 1 | Terminated | Helsinn Healthcare SA | 50 | 2023-06-17 | 2025-05-04 |
| Arnica Tincture Fot the Treatment of Cutaneous Leishmaniasis Arnica Tincture - Leishmaniasis, Cutaneous | Phase 1 | Active not recruiting | Universidad de Antioquia | 16 | 2023-05-03 | 2025-02-10 |
| Bioequivalence of IMP 08P1902F0 Relative to Contramal® (100 mg/mL Oral Solution) Tramadol Hydrochloride 5 MG/ML Oral Solution, Tramadol Hydrochloride 100 MG/ML Oral Solution (Contramal(r)) - Healthy | Phase 1 | Completed | Unither Pharmaceuticals, France | 24 | 2023-02-14 | 2024-12-16 |
| A Study of Genolair in Two Dosage Forms (Solution and Lyophilisate) and Xolair® in Healthy Volunteers Genolair, solution for subcutaneous administration, 150 mg, Genolair, lyophilisate for the preparation of solution for subcutaneous administration, Xolair®, solution for subcutaneous administration, 150 mg - Allergic Asthma | Phase 1 | Completed | AO GENERIUM | 180 | 2023-01-15 | 2024-07-10 |
| Amlodipine Freeze-Dried Powder for Oral Solution 5 mg Amlodipine Freeze-Dried Powder for Oral Solution 5 mg, Norvasc 5 mg tablets of Pfizer Labs - Hypertension, Coronary Artery Disease | Phase 1 | Completed | Brillian Pharma Inc. | 24 | 2022-12-29 | 2023-06-07 |
| Safety and Efficacy Study of Topical DLQ01 in the Treatment of Androgenetic Alopecia (AGA) in Men prostaglandin F2a analogue in vehicle solution high dose, prostaglandin F2a analogue in vehicle solution low dose, active ingredient-free vehicle solution to DLQ01 - Androgenetic Alopecia | Phase 1 / Phase 2 | Completed | Dermaliq Therapeutics, Inc. | 120 | 2022-12-05 | 2024-04-08 |
| JINZHEN for Treatment of Mild to Moderate COVID-19 JINZHEN Granules for Oral Solution, Placebo - COVID-19 | Phase 1 / Phase 2 | Completed | Lianyungang Kanion Group, Ltd. | 60 | 2022-05-26 | 2024-03-20 |
| A Study in Healthy Men to Test Whether BI 425809 Influences the Amount of Midazolam in the Blood midazolam, iclepertin (BI 425809) - Healthy | Phase 1 | Completed | Boehringer Ingelheim | 15 | 2022-03-18 | 2026-03-30 |
Showing 20 of 89. Sign in to see all of them.
Alopecia (2) · Bacterial Infections (2) · COVID-19 (2) · Diabetes Mellitus (2) · HIV Infections (2) · Hypertension (2) · Melanoma (2) · Neoplasm Metastasis (2) · Neoplasms (2) · Respiratory Distress Syndrome (2) · Acne Vulgaris (1) · Acquired Immunodeficiency Syndrome (1) · Acute Kidney Injury (1) · Acute Lung Injury (1) · Adenocarcinoma of Lung (1)
Boehringer Ingelheim (13) · GlaxoSmithKline (6) · AstraZeneca (4) · Dompé Farmaceutici S.p.A (3) · Takeda (3) · Bayer (2) · BioInvent International AB (2) · The University of Texas Health Science Center at San Antonio (2) · AO GENERIUM (1) · APR Applied Pharma Research s.a. (1) · ASST Fatebenefratelli Sacco (1) · Ahmed Hassan Nouh MD (1) · ApoPharma (1) · Barinthus Biotherapeutics (1) · Brillian Pharma Inc. (1)
United States (29) · United Kingdom (13) · Germany (9) · China (5) · Spain (4) · Belgium (3) · France (3) · Italy (3) · Russia (3) · Switzerland (3) · Canada (2) · South Korea (2) · Australia (1) · Colombia (1) · Denmark (1)
Abie Mendelsohn (1) · Andres McAllister, PhD (1) · Angela E Rankine- Mullings, MD (1) · Annelize Koch, Dr (1) · Bengt Larsson (1) · Betsy Hughes-Formella, PhD (1) · Brent Clary, CCRC (1) · Brian P Murray, DO (1) · Catherine Queille-Roussel, MD (1) · David D'Alessio, MD (1)
PMID 19620039, PMID 20115946, PMID 21199096, PMID 21712909, PMID 21899919, PMID 24720741, PMID 24949994, PMID 25601618, PMID 25765294, PMID 26448169, PMID 27184170, PMID 30807645, PMID 31245963, PMID 31321800, PMID 31405822, PMID 32478930, PMID 34168003, PMID 36808891, PMID 37939133, PMID 38129731, PMID 39406392, PMID 40825042, PMID 40932107, PMID 8517703
2014 (2), 2017 (2), 2016 (1), 2023 (1), 2025 (1), R01DK142423 (1)